Extensive AAV and lentiviral vector production capabilities & expertise
Yposkesi is a full-service CDMO, providing professional support through all stages of gene therapy development. We make available the entire viral vector manufacturing services necessary to enable you to rapidly and successfully develop ATMPs. You gain access to specialized expertise with integrated project management as well as streamlined and cost-efficient bioprocess development services:
GMP manufacturing of clinical & commercial batches
Yposkesi has four independent GMP manufacturing suites that can accommodate the installation of specific equipment, such as additional chromatography steps or a large size Single Use Bioreactor (up to 500L). The suites have an operational capacity of up to 33 batches per year Grade C rooms, which are operated at Biosafety level 2 for AAV and lentiviral processes. Both adherent (Cell Factory 10 devices / Hyperstack devices) and suspension processes (up to 2 * 200L Single Use Bioreactors) can be performed in these production rooms. Typical purification steps performed in these GMP areas cover: depth filtration, tangential flow filtration, chromatography (affinity, ion-exchange, size exclusion) and sterile filtration.
The company is currently extending its production capacity incorporating an additional 50,000 sq ft building equipped with large scale capacity, and suited for the manufacturing of post-registration products. This new plant will be fully operational by mid-2021. This new building will contain two production suites equipped with two 1,000 L bioreactor per suite.
- 2 Independent Manufacturing suites
- 2 x 1,000 L bioreactor scale per production line
- Operational capacity: up to 40 batches / year
- Bio Safety Level 2, Grade C rooms
- EMA & FDA compliant